Zyncof

Quick links to important sections

Zyncof

Method of action: Antitussive

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zyncof

Property Description
Active Ingredients Dextromethorphan Hydrobromide, Guaifenesin
Form Oral liquid (Syrup, Solution), Oral tablet
Pharmacological Class Antitussive and Expectorant Combination
General Purpose Symptomatic relief of cough and chest congestion
Origin Synthetic and derived (Guaifenesin)

1. Defining Zyncof: A Dual-Action Respiratory Combination

Zyncof is an oral medication classified as an Upper Respiratory Combination product, formulated to address two key symptoms associated with minor bronchial and airway irritations. This fixed-dose combination product is designed for systemic action to relieve cough and chest congestion and is commonly presented as an oral liquid or an oral tablet preparation. It is recognized in pharmacological literature for its ability to manage concurrent symptoms, a therapeutic approach for general respiratory discomfort. This classification confirms that the medicine works to ease both the dry cough reflex and the difficulty of mucus clearance.

2. Composition and Origin: Dextromethorphan Hydrobromide and Guaifenesin

The efficacy of Zyncof is derived from its dual composition of Dextromethorphan Hydrobromide and Guaifenesin, each with a distinct pharmacological role. Dextromethorphan Hydrobromide is a synthetically derived agent classified as an antitussive (cough suppressant), while Guaifenesin acts as an expectorant. Guaifenesin works by reducing the stickiness of the bronchial secretions. This specific combination is widely used globally and is categorized for cold and cough management. This categorization establishes the drug's role in the management of these prevalent symptoms.

3. General Purpose: Managing Cough and Chest Congestion

The general purpose of this specific combination is the simultaneous relief of two related physical discomforts: the constant urge to cough and the presence of thick secretions. The antitussive component works to quiet the central cough reflex, reducing the frequency of unproductive coughing fits. Concurrently, the expectorant component thins the viscosity of secretions in the airways, assisting the body in the effective clearance of thick mucus. This dual mechanism ensures the medication provides focused relief for both dry, irritating coughs and underlying chest congestion, a typical scenario when managing symptoms of the common cold or flu.

What side effects are possible with Zyncof?

Possible Side Effects and Safety Information: Zyncof

Zyncof is a combination medication typically containing Dextromethorphan (a cough suppressant), Chlorpheniramine (an antihistamine), and Phenylephrine (a nasal decongestant). As with any drug, it can cause side effects, although not everyone experiences them. Most side effects are mild and temporary.


Common Side Effects

The most frequently reported side effects are related to the antihistamine and antitussive components. These include:

  • Drowsiness or Sedation: This is a key side effect due to Chlorpheniramine and can impair the ability to drive or operate machinery.
  • Dizziness or Lightheadedness
  • Dry Mouth, Nose, or Throat
  • Nausea or Vomiting

Less Common, but Serious Side Effects

Consult a healthcare professional immediately if you experience signs of a serious reaction, such as:

  • Severe Allergic Reactions (Anaphylaxis): Including rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, or trouble breathing.
  • Cardiovascular Effects: Increased heart rate (tachycardia), palpitations, or significantly elevated blood pressure, primarily linked to Phenylephrine.
  • Central Nervous System Effects: Severe confusion, hallucinations, tremors, or seizures.

Safety Precautions and Warnings

Zyncof should be used with caution in patients with certain pre-existing conditions, including high blood pressure, heart disease, diabetes, glaucoma, thyroid problems (hyperthyroidism), or prostate enlargement (difficulty passing urine). The medication should not be used with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI), as this combination can cause a dangerous rise in blood pressure. Due to the risk of drowsiness, alcohol and other central nervous system depressants should be avoided while taking this medication. Dosage should be strictly followed, as abuse of Dextromethorphan can lead to serious adverse effects.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an overdose of Zyncof (Dextromethorphan/Guaifenesin) focuses primarily on severe effects related to central nervous system (CNS) toxicity and instability in the cardiovascular system.

Documented Overdose Manifestations

Overdose exposure may result in CNS signs ranging from confusion, hallucinations, ataxia (unsteady gait), and nystagmus (involuntary eye movement), progressing to profound drowsiness or coma and seizures. Cardiovascular effects such as tachycardia (rapid heart rate) and hypertension (high blood pressure) are also documented. A life-threatening outcome associated with severe exposure is the development of Serotonin Syndrome.

Immediate Emergency Actions

It is documented that any suspected overdose requires immediately seeking medical attention. Immediate emergency services must be contacted if the individual has collapsed, experienced a seizure, has trouble breathing or slowed, shallow breathing, or cannot be awakened. Consulting a Poison Control Center is also officially recommended.

Management and Classification

Management is defined as symptomatic and supportive. There is no specific antidote known for this combination. However, procedural steps described include the monitoring of vital signs and the potential use of agents like activated charcoal or benzodiazepines to manage specific toxic manifestations such as agitation and seizures. Individuals taking other serotonergic medications are noted to have an increased risk for severe complications like Serotonin Syndrome.

Therapeutic Uses of Zyncof

Zyncof may be part of symptomatic management for symptoms related to systemic imbalance and discomfort, which are often associated with acute respiratory episodes. Its components are applied when appropriate to temporarily relieve cough and chest congestion stemming from conditions like the common cold. The medication is commonly used across conditions presenting with acute episodes, such as the common cold, flu, and minor bronchial or throat irritations.

“Applied across domains where additional symptomatic support is needed, Zyncof helps address symptom clusters that may become intense or disruptive.”


Supportive Relief for Disruptive Cough Symptoms

This therapeutic domain is applied across areas where short-term symptom management is appropriate, particularly for the irritating cough that interferes with daily functioning. Zyncof helps address symptom clusters that may become intense or disruptive by providing support that helps ease the overall symptom burden and supports the patient in managing temporary functional strain.


Easing Acute Episodes of Chest Congestion

This is relevant in contexts marked by increased discomfort or tension, specifically for symptoms related to physical discomfort such as chest congestion and excessive mucus. The medication is commonly used to help with managing symptoms that create noticeable physiological strain, which contributes to improved day-to-day comfort during periods of heightened symptoms.


Quick Fact: Relief for Dual Respiratory Discomfort

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Zyncof (Dextromethorphan Hydrobromide and Guaifenesin) is strictly defined by regulatory guidelines concerning age, existing medical conditions, and concurrent medication use.

Populations for Whom Use is Contraindicated

  • Monoamine Oxidase Inhibitors (MAOIs): Use is absolutely forbidden in patients currently taking an MAO inhibitor or who have discontinued one within the preceding 14 days.
  • Hypersensitivity: Individuals with a known allergy or hypersensitivity to Dextromethorphan, Guaifenesin, or any excipients in the specific formulation.

Age-Related Eligibility Rules

  • Adults and Adolescents: The approved population for standard use is Age 12 and Over.
  • Pediatric Patients: Use in children under 12 years of age is generally not recommended on most product labels. The FDA and health agencies strongly advise against giving any OTC cough and cold product containing these ingredients to children under 4 years of age due to unestablished safety.

Conditional Use Restrictions

  • Chronic Cough: Official labeling advises that the medicine should not be used for chronic cough (e.g., associated with smoking, asthma, or COPD) or a cough accompanied by excessive phlegm/mucus, unless directed by a health professional.
  • Organ Function/Comorbidity: Caution is required, and professional consultation is necessary, for patients with severe hepatic or renal impairment or certain metabolic disorders like Phenylketonuria (PKU) (depending on formulation).
  • Pregnancy and Lactation: The label instructs patients who are pregnant or breast-feeding to ask a health professional before use due to limited data and the recommendation to avoid alcohol-containing liquid formulations.

The regulatory profile thus defines eligibility by excluding populations where the drug carries a high risk of adverse reactions or where safety has not been established, limiting use to individuals who meet the approved age and health criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official government regulatory information outlines a critical restriction regarding the use of Zyncof (a product containing Dextromethorphan and Guaifenesin) in combination with other prescription medicines.

Documented Interaction Restrictions

Regulatory documents explicitly state that Zyncof must not be used concurrently with, or within a specific time frame of stopping, prescription Monoamine Oxidase Inhibitor (MAOI) drugs. This prohibition is due to the potential for a dangerous drug interaction.

Product Category Restriction Details
Monoamine Oxidase Inhibitors (MAOI) Do not use Zyncof if you are currently taking, or for 2 weeks after stopping, a prescription MAOI.

MAOIs are a class of medicines used to treat certain conditions, including depression, other psychiatric or emotional conditions, or Parkinson's disease. The restriction applies to specific interacting prescription medicines in this class, and patients are advised to consult a healthcare professional if they are uncertain whether their prescription drug contains an MAOI before using Zyncof. This requirement for avoidance constitutes the primary interaction-related constraint defined in the official product labeling, establishing an implicit contraindication for co-administration. The interaction profile is structured to enforce a necessary period of separation between the two product classes to ensure patient safety.

Mechanism of Action

Central Modulation of the Cough Reflex Threshold

This domain centers on the antitussive action of Dextromethorphan as an agonist at the Sigma-1 (sigma1) receptor within the brainstem. This molecular action targets the Central Cough Reflex Pathway by raising the intrinsic excitability threshold of the medullary cough center, which decreases the responsiveness to afferent tussigenic stimuli.

Peripheral Regulation of Airway Secretion Hydration

This domain involves the expectorant action of Guaifenesin, which influences the Respiratory Mucus Hydration Pathway. The mechanism, mediated by the gastropulmonary vagal reflex arc and/or direct systemic effects on bronchial secretory cells, promotes the secretion of water into the airways. This physiological change effectively decreases the viscosity of the bronchial secretions, which is a prerequisite for enhanced mucociliary transport.

Functional Coordination of Mechanistic Effects

These two mechanisms act simultaneously: the central mechanism acts to reduce the responsiveness of the medullary center, while the peripheral mechanism increases the mobilization potential of the secretions.

Dosage and Administration Information

How to Use Zyncof (Dextromethorphan HBr and Guaifenesin Syrup)

This section outlines the administration information for Zyncof syrup.

Administration Protocol

Zyncof is an oral liquid (syrup) that must be measured and taken by mouth.

Scope Component Details
Route of Administration Oral route only
Strength Per Dose 20 mg Dextromethorphan HBr and 400 mg Guaifenesin in 5 mL

Dosing and Frequency

The standard dosing regimen establishes both the amount and the maximum frequency of administration.

Dosing Parameter Rule
Single Dose 5 mL (equivalent to one teaspoon)
Frequency Repeat every 4 hours as needed
Maximum Limit Do not take more than 6 doses in any 24-hour period

Age-Group and Procedural Rules

It is essential to adhere to the population-specific use constraints.

  • Adults and Children 12 Years of Age and Over: The approved dose is 5 mL.
  • Children Under 12 Years of Age: This product is not approved for use in this age group.
  • Measurement: Always use an accurate milliliter (mL) measuring device, such as a dosing spoon or cup, to ensure the correct 5 mL dose is administered.
  • Course Duration: Stop use and consult a healthcare professional if the condition worsens or persists for more than 7 days.

Recent Clinical Evidence

Research evidence / Overview of studies for Zyncof


Evidence for Acute Cough Associated with the Common Cold

Research examining the effects of the combination in Zyncof focuses on the component Dextromethorphan and the component Guaifenesin. Short-term, randomized controlled trials (RCTs) was used in research exploring how symptoms change over time in adults with acute cough stemming from conditions like the common cold. These studies focused on measuring both the total number of coughs (an objective measure) and patient-reported outcomes describing perceived discomfort and cough intensity over short time periods.

Research has explored whether Dextromethorphan is associated with patterns of change in the frequency of coughing episodes in individuals, particularly during episodes where symptoms become more noticeable. However, the findings were mixed across various studies, with some trials reporting data show patterns related to a measured change and others finding little difference when compared to an inactive control. The evidence base for the individual components is often noted in scientific literature that describes the combination product.


Evidence for Symptomatic Relief of Chest Congestion and Thick Mucus

Research examined the Guaifenesin component in contexts related to managing outcomes related to physical discomfort such as chest congestion and thick mucus. Researchers primarily used short-term RCTs to assess how this component affects secretions in the airways of patients with acute respiratory conditions. Outcomes research examined included objective lab measurements of mucus thickness and patient-reported outcomes describing perceived discomfort and the ease of clearing the chest.

Findings describe patterns observed in the studies where some individuals reported changes in their perceived congestion and the thickness of secretions. However, the evidence is challenging to interpret consistently. Measuring objective changes in mucus clearance during an acute illness was observed in some studies to be difficult, which can make the evidence challenging to interpret consistently.


Unanswered Questions and Research Limitations

The overall evidence landscape has several documented limitations. A key gap is the limited information from dedicated, large-scale RCTs that directly compare the specific fixed-dose combination (Zyncof) to placebo to clearly isolate the combined effect. Furthermore, follow-up durations were limited, typically only covering the acute, self-limiting phase of the illness, which means long-term effects are not fully established. The challenge of objectively measuring cough and mucus viscosity means that the findings were mixed across studies, and the evidence is not yet conclusive in some areas. Research provides insight into short-term changes, and findings describe group patterns, not personal outcomes, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Systematic review of randomised controlled trials of over the counter cough medicines for acute cough in adults
  2. Dextromethorphan and Guaifenesin: MedlinePlus Drug Information
  3. Guaifenesin: MedlinePlus Drug Information
  4. Dextromethorphan: MedlinePlus Drug Information
  5. Guaifenesin and Dextromethorphan HBR extended release tablet label (DailyMed/NIH)
  6. Summary of the evidence: Cough (acute) - NICE Guideline NG120

Frequently Asked Questions (FAQ)

Common questions about Zyncof (FAQ)


Q: Are there any specific foods or drinks to avoid while using Zyncof?

Official product information advises avoiding alcohol and other central nervous system depressants due to the risk of increased side effects like drowsiness. The medication can generally be taken with or without food. Official guidance suggests taking Zyncof with food if stomach upset occurs.


Q: Is it possible to develop a dependence on Zyncof?

While the active ingredients themselves are not typically classified as scheduled controlled substances, regulatory documents warn against the improper use (abuse) of the medication. Official sources indicate that the improper use of the medication may lead to serious adverse effects like seizures, brain damage, or death.


Q: Are there any long-term safety concerns associated with using Zyncof?

Official instruction states that Zyncof should only be used for short-term relief of acute symptoms. The medication is not intended for chronic use. Regulatory guidance states that use should be discontinued if the condition worsens or persists for more than seven days.


Q: What are the most commonly reported side effects of Zyncof in official research?

Official information regarding the components of Zyncof reports common effects such as dizziness, drowsiness, nausea, vomiting, abdominal pain, and headache. These effects are typically reported as mild and temporary. Specific prevalence rates (how often people experience them) are not routinely detailed in patient-facing regulatory documents.


Q: Is it true that Zyncof interacts with certain common cold medicines?

Yes, official warnings strictly prohibit using Zyncof with, or within 14 days of stopping, a Monoamine Oxidase Inhibitor (MAOI). Regulatory guidance also advises carefully checking the labels of other cold or allergy medicines. This is to avoid the risk of increased side effects or excessive total doses of shared active ingredients.


Q: What does 'contraindication' mean in the context of Zyncof use?

A contraindication is a condition or factor that provides a reason to withhold a specific medical treatment because of the harm it could cause the patient. For Zyncof, using the drug concurrently with a Monoamine Oxidase Inhibitor (MAOI) is defined as a primary contraindication in regulatory documents.


Q: Can Zyncof be taken if I am already taking an antidepressant?

Zyncof is strictly contraindicated if a person is taking a Monoamine Oxidase Inhibitor (MAOI) or has stopped taking one within the last 14 days. Official safety information includes a caution regarding combining Zyncof with certain other types of antidepressants, such as SSRIs, due to the potential for a serious condition known as serotonin syndrome.


Q: How is the safety profile of Zyncof described in regulatory documents?

The safety profile, as described in regulatory information, includes explicit warnings regarding serious risks, such as severe allergic reactions and the potential for abuse. Furthermore, it contains precautions detailing that use in patients with certain pre-existing conditions (e.g., heart disease) should be approached cautiously.


Q: What are the general expectations for relief when using Zyncof?

Zyncof is intended to temporarily relieve cough caused by the common cold or flu. Regulatory data indicates that the antitussive (cough-relieving) component, dextromethorphan, generally begins to exert its effect within 15 to 30 minutes after being taken.


Q: Does Zyncof come in different forms, like liquid or tablets?

The Zyncof product is described as an oral liquid or syrup. However, the active components of Zyncof are widely available in other forms. Official labeling for these ingredients includes tablets (immediate and extended-release) and liquid-filled capsules.


Q: Why is Zyncof usage restricted for certain medical conditions?

Usage is restricted or cautioned for conditions like high blood pressure, heart problems, and an overactive thyroid. This is primarily because the decongestant component, phenylephrine, has the potential to increase heart rate or raise blood pressure.


Q: Are there specific symptoms that require stopping Zyncof immediately?

Yes, official regulatory instruction indicates that use should be discontinued and medical attention sought if the condition worsens or persists for more than seven days. Other symptoms that require immediate medical attention include fever, rash, a persistent headache, signs of severe allergic reactions, or symptoms related to misuse.


Q: What does the FDA label say about Zyncof's potential for abuse?

The FDA label and related official documents warn that improper use (abuse) of the medication, particularly due to the dextromethorphan component, can lead to serious adverse effects. These effects include the risk of brain damage, seizure, or death.


Q: How does Zyncof affect sleep patterns?

The official side effect profile lists drowsiness and sedation as common effects, primarily due to the antihistamine component. These ingredients can impact alertness and cause trouble sleeping. This effect is often more noticeable when the medication is taken with alcohol or other sedatives.


Q: Does Zyncof treat all kinds of coughs, or just specific ones?

Zyncof is indicated to temporarily relieve cough caused by acute conditions like the common cold or the flu. Official product information indicates that it is not recommended for a chronic cough, such as one associated with smoking or asthma, or a cough with excessive mucus, unless a healthcare professional has been consulted.


Q: What should I do if I accidentally miss a dose of Zyncof?

According to official labeling, if a dose is missed, it should be taken as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the missed dose should be skipped entirely. Product labeling indicates that a double dose should not be taken to catch up.


Q: Is Zyncof classified as a narcotic or controlled substance?

The product is not typically classified as a scheduled controlled substance when sold as an over-the-counter combination cough and cold medication. The active components, such as Dextromethorphan and Chlorpheniramine, are generally available over-the-counter (OTC).


Q: What official body (like the FDA) approved Zyncof for use?

The product's usage and regulatory oversight are governed by the U.S. Food and Drug Administration (FDA) regulations. This includes the rules for over-the-counter combination drug products that contain Dextromethorphan, Guaifenesin, Chlorpheniramine, and Phenylephrine.


Q: Can Zyncof be used while breastfeeding?

Regulatory information indicates that the cough and expectorant components are generally considered safe during breastfeeding. However, regulatory information notes that caution is warranted because the decongestant component (phenylephrine) may potentially reduce milk supply, and the antihistamine component can cause infant drowsiness.


Q: Is there a generic version of Zyncof available?

Yes, the active ingredients found in Zyncof—Dextromethorphan, Guaifenesin, Chlorpheniramine, and Phenylephrine—are widely available. These components can be found in multiple generic and brand-name products on the market.


Q: Do studies suggest Zyncof is equally effective across all age groups?

Official texts note that Zyncof is only approved for use in individuals aged 12 and over. Regulatory text states that the efficacy and safety in children under the age of 12 are often questioned or not established by studies.


Q: How does Zyncof affect people who have asthma?

Regulatory information explicitly states that Zyncof is not recommended for a cough that is chronic or persistent, such as a cough associated with asthma or emphysema. Use of the product for these conditions is reserved for situations when specifically advised by a healthcare professional.


Q: Why does the label mention a warning about kidney function?

Warnings for use in patients with kidney problems are included in the precautions list found in official labeling. This is due to the fact that the kidneys are a primary route for eliminating the medication's components from the body.


Q: Can Zyncof interact with herbal supplements like St. John's Wort?

Official documentation shows that the herbal supplement St. John’s Wort is known to interact with medications containing these cold components.


Q: Does research show any specific risk for older adults taking Zyncof?

While specific combination risks are not detailed, the antihistamine component (chlorpheniramine) is associated with an increased burden of side effects in older adults. These effects include potential anticholinergic effects, which may affect alertness and physical function.


Q: Is Zyncof a treatment for the underlying condition or just the symptom?

Zyncof is classified as an antitussive (cough suppressant) and an expectorant (mucus thinner). Its mechanism of action works to relieve the symptoms of cough and congestion, but it will not treat the cause of the illness or speed recovery.


Q: Is it normal to feel a mild headache after starting Zyncof?

Yes, headache is listed in the official side effect profiles as a potential effect of the components in Zyncof.


Q: Can Zyncof be used by people who have liver disease?

Official regulatory information notes that caution is warranted for use in patients who have liver disease. This caution is in place because the components of the medication are metabolized in the liver, and impairment of liver function may lead to high drug levels.


Q: Why do official sources sometimes use different names for Zyncof?

Official sources may use different systems of nomenclature, such as the International Nonproprietary Name (INN) or the United States Adopted Name (USAN), for the active components. For example, the antihistamine component may be referred to as Chlorphenamine or Chlorpheniramine depending on the source.


Q: Can Zyncof be taken on an empty stomach?

Yes, official regulatory information indicates that Zyncof can generally be taken with or without food. Taking the medication with food is advised if it causes stomach upset.

How should Zyncof be stored and disposed of?

How to Store and Dispose of Zyncof

Zyncof must be stored at a controlled room temperature, specifically maintained between 15 C to 30 C (59 F to 86 F). The product requires protection from excessive heat and humidity, and certain liquid formulations must be protected from light.

Storage Constraints

The medication must be secured out of the reach of children and pets. It is required to keep Zyncof in its original container with the closure tightly closed. Liquid formulations must not be frozen and should not be stored in a bathroom.

Disposal Instructions

Unused or expired Zyncof should not be flushed down the toilet or poured down a drain. The preferred method for disposal is the use of a community drug take-back program. When no take-back option is available, the product should be mixed with an unappealing substance, sealed in a bag, and disposed of in the household trash, in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zyncof found in:

A-Z Index: